EXCLUSIVE – 10 years after its creation, medtech company NovaGray has signed a decisive partnership with Eurofins Biomnis to enable breast cancer patients to assess their resistance to radiotherapy.
Nearly 30 years of work have come to fruition. ” We founded NovaGray in 2015 with Professor David Azria, an oncologist. When we met in 2015, he had been working for nearly 20 years on developing tests to assess patients’ tolerance to radiotherapy ,” says Clemence Franc, CEO of NovaGray.